Page 20 - 《中国药房》2025年16期

tion of meropenem in plasma and filtrate-dialysate from nal function[J]. Infect Drug Resist，2022，15：53-62.
patients under continuous veno-venous haemodiafiltration [68] SCHARF C，PAAL M，SCHROEDER I，et al. Therapeutic
by SPE-LC[J]. J Pharm Biomed Anal，2002，29（1/2）： drug monitoring of meropenem and piperacillin in critical
17-33. illness-experience and recommendations from one year in
[57] FERRONE V，COTELLESE R，CICHELLA A，et al. Me‐ routine clinical practice[J]. Antibiotics（Basel），2020，9
ropenem and ciprofloxacin in complicated gastric surgery （3）：131.
for cancer patients：a simple SPE-UHPLC-PDA method [69] TRUONG A Q，DAO X C，VU D H，et al. Optimizing me‐
for their determination in human plasma[J]. Biomed Chro‐ ropenem in highly resistant Klebsiella pneumoniae envi‐
matogr，2019，33（3）：e4450. ronments：population pharmacokinetics and dosing simula‐
[58] YANG P，ZHANG X H，ZHOU C Y，et al. Determination tions in critically ill patients[J]. Antimicrob Agents Che‐
of free and total meropenem levels in human plasma and mother，2022，66（11）：e0032122.
its application for the consistency evaluation of generic [70] BASTIDA C，HERNÁNDEZ-TEJERO M，AZIZ F，et al.
drugs[J]. Rapid Commun Mass Spectrom，2023，37（5）： Meropenem population pharmacokinetics in patients with
e9460. decompensated cirrhosis and severe infections[J]. J Anti‐
[59] MARTENS-LOBENHOFFER J，BODE-BÖGER S M. microb Chemother，2020，75（12）：3619-3624.
Quantification of meropenem in human plasma by HILIC- [71] TRANG M，GRIFFITH D C，BHAVNANI S M，et al.
tandem mass spectrometry[J]. J Chromatogr B，2017， Population pharmacokinetics of meropenem and vaborbac‐
1046：13-17. tam based on data from noninfected subjects and infected
[60] HUANG L S，HAAGENSEN J，VEROTTA D，et al. De‐ patients[J]. Antimicrob Agents Chemother，2021，65（9）：
termination of meropenem in bacterial media by LC-MS/ e0260620.
MS[J]. J Chromatogr B Analyt Technol Biomed Life Sci， [72] ABULFATHI A A，DE JAGER V，VAN BRAKEL E，et al.
2014，961：71-76. The population pharmacokinetics of meropenem in adult
[61] 国家药品监督管理局药品审评中心.化学药物临床药代 patients with rifampicin-sensitive pulmonary tuberculosis
动力学研究技术指导原则[EB/OL]. [2025-05-25]. https：// [J]. Front Pharmacol，2021，12：637618.
www.cde.org.cn/zdyz/downloadAtt?idCODE=a5b42ca1e- [73] YANG Y J，WANG Y R，ZENG W，et al. Physiologically-
9770de4bd19091f428c436d. based pharmacokinetic/pharmacodynamic modeling of
[62] LIEBCHEN U，SALLETMEIER H，KALLEE S，et al. Op‐ meropenem in critically ill patients[J]. Sci Rep，2024，14
timal loading dose of meropenem before continuous infu‐ （1）：19269.
sion in critically ill patients：a simulation study[J]. Sci [74] O’JEANSON A，LARCHER R，LE SOUDER C，et al.
Rep，2021，11（1）：17211. Population pharmacokinetics and pharmacodynamics of
[63] JAMAL J A，MAT-NOR M B，MOHAMAD-NOR F S，et meropenem in critically ill patients：how to achieve best
al. Pharmacokinetics of meropenem in critically ill pa‐ dosage regimen according to the clinical situation[J]. Eur
tients receiving continuous venovenous haemofiltration：a J Drug Metab Pharmacokinet，2021，46（5）：695-705.
randomised controlled trial of continuous infusion versus [75] LAN J H，WU Z，WANG X P，et al. Population pharmaco‐
intermittent bolus administration[J]. Int J Antimicrob kinetics analysis and dosing simulations of meropenem in
Agents，2015，45（1）：41-45. critically ill patients with pulmonary infection[J]. J Pharm
[64] LANGGARTNER J，VASOLD A，GLÜCK T，et al. Phar‐ Sci，2022，111（6）：1833-1842.
macokinetics of meropenem during intermittent and con‐ [76] TIAN X，DONG L，JIANG T T，et al. Meropenem for chil‐
tinuous intravenous application in patients treated by con‐ dren with severe pneumonia：protocol for a randomized
tinuous renal replacement therapy[J]. Intensive Care Med， controlled trial[J]. Front Pharmacol，2022，13：1021661.
2008，34（6）：1091-1096. [77] 中国医药教育协会感染疾病专业委员会. 抗菌药物药代
[65] 陈文倩，杭永付，张丹，等 . f%T＞MIC 计算模型的建立 动力学/药效学理论临床应用专家共识[J]. 中华结核和
及重症患者碳青霉烯类抗菌药物个体化用药方案的优 呼吸杂志，2018，41（6）：409-446.
化[J]. 中国药学杂志，2018，53（15）：1313-1317. [78] DELATTRE I K，TACCONE F S，JACOBS F，et al. Opti‐
[66] ABDUL-AZIZ M H，ALFFENAAR J C，BASSETTI M， mizing β-lactams treatment in critically-ill patients using
et al. Antimicrobial therapeutic drug monitoring in criti‐ pharmacokinetics/pharmacodynamics targets：are first con‐
cally ill adult patients：a position paper[J]. Intensive Care ventional doses effective?[J]. Expert Rev Anti Infect Ther，
Med，2020，46（6）：1127-1153. 2017，15（7）：677-688.
[67] GIJSEN M，ELKAYAL O，ANNAERT P，et al. Merope‐ [79] BEUMIER M，CASU G S，HITES M，et al. Elevated
nem target attainment and population pharmacokinetics in β-lactam concentrations associated with neurological dete‐
critically ill septic patients with preserved or increased re‐ rioration in ICU septic patients[J]. Minerva Anestesiol，

· 1966 · China Pharmacy 2025 Vol. 36 No. 16 中国药房 2025年第36卷第16期